Haemoadsorption During Heart Transplantation (CytoSorbHTX)
Primary Purpose
Heart Transplantation
Status
Recruiting
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
CytoSorb Adsorber
Sponsored by

About this trial
This is an interventional treatment trial for Heart Transplantation focused on measuring Heart Transplantation, Cytosorb
Eligibility Criteria
Inclusion Criteria:
- Adult patients undergoing heart transplantation
Exclusion Criteria:
- Declined informed consent
- Age < 18 years#
- Receiving antileukocyte drugs
- Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
- DCD
- Ex-vivo perfusion
Sites / Locations
- Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of ViennaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Adsorber Group
Control
Arm Description
Surgery with CPB will be performed according to institutional standards, depending on indications and surgical preferences. For the intervention group (adsorber-group), the CytoSorb adsorber will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 300-400 ml.min-1.
The control group (no-adsorber group) will be treated similarly, but no filter circuit will be installed.
Outcomes
Primary Outcome Measures
Difference in maximal cytokine peak levels (IL-1β, IL-6, IL-33, TNF-α, IL-10)
Difference in maximal cytokine peak levels in various cytokine levels compared to baseline measured by ELISA
Secondary Outcome Measures
Difference of immunosuppression (TTV)
Individual immunosuppression measured by Torque-teno-virus load
Difference of immunosuppression (sST2)
Individual immunosuppression measured by sST2 levels
primary graft dysfunction score
Differences in primary graft dysfunction score between both groups
30-day mortality
Differences in 30-day mortality between both groups
Mechanical Ventilation
Differences in length of mechanical ventilation
Delirium
Differences in Confusion assessment method for the ICU between both groups
Full Information
NCT ID
NCT05270902
First Posted
February 2, 2022
Last Updated
March 13, 2023
Sponsor
Medical University of Vienna
1. Study Identification
Unique Protocol Identification Number
NCT05270902
Brief Title
Haemoadsorption During Heart Transplantation
Acronym
CytoSorbHTX
Official Title
Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of Vienna
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and induces a decreased inflammatory response, increased anti-inflammatory response or immunosuppressive response. Additionally, the influence of HA on primary graft dysfunction, postoperative cerebral dysfunction, postoperative fluid accumulation, renal dysfunction, duration of mechanical ventilation, length of ICU-stay and 30-day mortality should be investigated
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Transplantation
Keywords
Heart Transplantation, Cytosorb
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, single-center, single-blinded, randomized, controlled trial
Masking
Participant
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Adsorber Group
Arm Type
Active Comparator
Arm Description
Surgery with CPB will be performed according to institutional standards, depending on indications and surgical preferences.
For the intervention group (adsorber-group), the CytoSorb adsorber will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 300-400 ml.min-1.
Arm Title
Control
Arm Type
No Intervention
Arm Description
The control group (no-adsorber group) will be treated similarly, but no filter circuit will be installed.
Intervention Type
Device
Intervention Name(s)
CytoSorb Adsorber
Intervention Description
Polymer based adsorber system for the elimination of cytokines
Primary Outcome Measure Information:
Title
Difference in maximal cytokine peak levels (IL-1β, IL-6, IL-33, TNF-α, IL-10)
Description
Difference in maximal cytokine peak levels in various cytokine levels compared to baseline measured by ELISA
Time Frame
5 days
Secondary Outcome Measure Information:
Title
Difference of immunosuppression (TTV)
Description
Individual immunosuppression measured by Torque-teno-virus load
Time Frame
30days
Title
Difference of immunosuppression (sST2)
Description
Individual immunosuppression measured by sST2 levels
Time Frame
30days
Title
primary graft dysfunction score
Description
Differences in primary graft dysfunction score between both groups
Time Frame
7 days
Title
30-day mortality
Description
Differences in 30-day mortality between both groups
Time Frame
30 days
Title
Mechanical Ventilation
Description
Differences in length of mechanical ventilation
Time Frame
up to 4 weeks
Title
Delirium
Description
Differences in Confusion assessment method for the ICU between both groups
Time Frame
5 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients undergoing heart transplantation
Exclusion Criteria:
Declined informed consent
Age < 18 years#
Receiving antileukocyte drugs
Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
DCD
Ex-vivo perfusion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Martin H. Bernardi, MD, PhD
Phone
0043140400
Ext
41090
Email
martin.bernardi@meduniwien.ac.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin H. Bernardi, MD, PhD
Organizational Affiliation
Medical University of Vienna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of Vienna
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin H Bernardi, MD
Phone
004314040041090
Email
martin.bernardi@meduniwien.ac.at
First Name & Middle Initial & Last Name & Degree
Martin H Bernardi, MD
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
after completion of study, the results will be published in a peer reviewed journal
Learn more about this trial
Haemoadsorption During Heart Transplantation
We'll reach out to this number within 24 hrs